Merck KGaA drops pipeline assets from SpringWorks buyout, Hengrui licensing deal
Fuente:
FierceBiotech
Merck KGaA is no longer pursuing clinical-stage candidates obtained through its $3.9 billion acquisition of SpringWorks, which centered on approved drugs.